keyword
https://read.qxmd.com/read/38570210/effectiveness-and-safety-of-adalimumab-biosimilar-in-patients-with-inflammatory-bowel-disease
#1
JOURNAL ARTICLE
Jaime E Poquet-Jornet, Inés Ibáñez-Sala, Teresa Garrigues-Pelufo, Adrián Munilla-Das, Antonio Valdivia-Pérez, Francisco Javier Carrera-Hueso
BACKGROUND: Adalimumab biosimilar MSB11022 (Idacio ®) has been approved for the same indications as its originator (Humira ®), based on findings from clinical trials in plaque psoriasis. Data on its efficacy and safety in inflammatory bowel disease, however, are scarce. METHODS: Retrospective, observational study of 44 patients with inflammatory bowel disease: 30 were treated with originator adalimumab, 5 were directly started on MSB11022, and 9 switched from originator to biosimilar adalimumab...
April 2, 2024: Farmacia Hospitalaria
https://read.qxmd.com/read/38555555/immunopathogenesis-of-urticaria-a-clinical-perspective-on-histamine-and-cytokine-involvement
#2
REVIEW
Rudranil Bhowmik, Md Adil Shaharyar, Arnab Sarkar, Avishek Mandal, Kumar Anand, Humira Shabana, Achintya Mitra, Sanmoy Karmakar
BACKGROUND: Urticaria is a clinical condition characterized by the appearance of wheals (hives), angioedema, or both. Over the last several decades, a better understanding of the mechanisms at play in the immunopathogenesis of urticaria has underscored the existence of numerous urticaria subtypes. Separating the different kinds of urticaria explicitly helps find the best detection method for the management of this skin disorder. Subtypes of urticaria also include both spontaneous and physical types...
March 31, 2024: Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.]
https://read.qxmd.com/read/38514505/-totality-of-evidence-approach-in-the-development-of-gp2017-an-approved-adalimumab-biosimilar
#3
REVIEW
Norman Gaylis, Charlotte Both, Lena Lemke, Oliver von Richter, Paul Yamauchi
INTRODUCTION: Hyrimoz® , (GP2017 [SDZ-ADL]), is a biosimilar to Humira® (REF-ADL). SDZ-ADL was approved in 2018 by both the United States Food and Drug Administration (US FDA) and European Medicines Agency (EMA) for the indications of REF-ADL not protected by orphan exclusivity. In 2023, the US FDA and EMA also approved a citrate-free high-concentration formulation (HCF) of SDZ-ADL. TOTALITY OF EVIDENCE-THE APPROACH: Approval of SDZ-ADL was based on data gathered using the US FDA, EMA and World Health Organization (WHO)-recommended step-wise Totality of Evidence approach...
March 21, 2024: Advances in Therapy
https://read.qxmd.com/read/38501729/long-term-control-of-diabetes-by-tofacitinib-based-immunosuppressive-regimen-after-allo-islet-transplantation-in-diabetic-rhesus-monkeys-that-rejected-previously-transplanted-porcine-islets
#4
JOURNAL ARTICLE
Jong-Min Kim, Seong-Jun Kang, So-Hee Hong, Hyunwoo Chung, Jun-Seop Shin, Byoung-Hoon Min, Hyun Je Kim, Jongwon Ha, Chung-Gyu Park
Porcine islet xenotransplantation has been highlighted as an alternative to allo islet transplantation. Despite the remarkable progress that has been made in porcine-islet pre-clinical studies in nonhuman primates, immunological tolerance to porcine islets has not been achieved to date. Therefore, allo islet transplantation could be required after the failure of porcine islet xenotransplantation. Here, we report the long-term control of diabetes by allogeneic pancreatic islet transplantation in diabetic rhesus monkeys that rejected previously transplanted porcine islets...
March 2024: Xenotransplantation
https://read.qxmd.com/read/38496097/granulomas-galore-concomitant-granulomatous-infections-in-a-patient-with-crohn-s-disease
#5
Michael Gianarakis, Alexander Gianarakis, Safia Ahmed, John Pueringer, Ushan Ranasinghe
Tumor necrosis factor (TNF)-alpha inhibitors are effective biologics in the treatment of inflammatory bowel disease; however, they increase susceptibility to opportunistic infections. We report a case of a 74-year-old female with Crohn's disease who developed concomitant pulmonary tuberculosis ( Mycobacterium tuberculosis [MTB]) and Histoplasmosis capsulatum  infection while on adalimumab. Co-infection is rare in patients on TNF-alpha inhibitor therapy, and most cases have been reported in patients with human immunodeficiency virus (HIV)...
February 2024: Curēus
https://read.qxmd.com/read/38484684/silicon-a-quasi-essential-element-availability-in-soil-fertilizer-regime-optimum-dosage-and-uptake-in-plants
#6
REVIEW
Vandana Thakral, Gaurav Raturi, Sreeja Sudhakaran, Rushil Mandlik, Yogesh Sharma, S M Shivaraj, Durgesh Kumar Tripathi, Humira Sonah, Rupesh Deshmukh
The essentiality of silicon (Si) has always been a matter of debate as it is not considered crucial for the lifecycles of most plants. But beneficial effects of endogenous Si and its supplementation have been observed in many plants. Silicon plays a pivotal role in alleviating the biotic and abiotic stress in plants by acting as a physical barrier as well as affecting molecular pathways involved in stress tolerance, thus widely considered as "quasi-essential". In soil, most of Si is found in complex forms as mineral silicates which is not available for plant uptake...
February 22, 2024: Plant Physiology and Biochemistry: PPB
https://read.qxmd.com/read/38466559/relevance-of-adalimumab-product-attributes-to-patient-experience-in-the-biosimilar-era-a-narrative-review
#7
REVIEW
Jessica R Allegretti, Jessica H Brady, Ann Wicker, Mark Latymer, Alvin Wells
Adalimumab (ADL, Humira® , reference product), an anti-TNF-α biologic, has transformed the treatment of chronic, immune-mediated inflammatory diseases. However, the high cost of ADL therapy has driven the development of more affordable ADL biosimilars, agents with no clinically meaningful differences from the reference product. This review summarizes the product attributes of reference ADL and the nine ADL biosimilars approved and available in the USA in relation to patient experience of injection-site pain (ISP)...
March 11, 2024: Advances in Therapy
https://read.qxmd.com/read/38466213/mirikizumab-omvoh-for-ulcerative-colitis
#8
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 18, 2024: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/38420577/unveiling-the-contemporary-progress-of-graphene-based-nanomaterials-with-a-particular-focus-on-the-removal-of-contaminants-from-water-a-comprehensive-review
#9
REVIEW
Humira Assad, Imtiyaz Ahmad Lone, Alok Kumar, Ashish Kumar
Water scarcity and pollution pose significant challenges to global environmental sustainability and public health. As these concerns intensify, the quest for innovative and efficient water treatment technologies becomes paramount. In recent years, graphene-based nanomaterials have emerged as frontrunners in this pursuit, showcasing exceptional properties that hold immense promise for addressing water contamination issues. Graphene, a single layer of carbon atoms arranged in a hexagonal lattice, exhibits extraordinary mechanical, electrical, and chemical properties...
2024: Frontiers in Chemistry
https://read.qxmd.com/read/38366636/prime-editing-in-plants-prospects-and-challenges
#10
JOURNAL ARTICLE
Sanskriti Vats, Jitesh Kumar, Humira Sonah, Feng Zhang, Rupesh Deshmukh
Prime editors are reverse transcriptase (RT)-based genome editing tools utilizing double strand break (DSB) free mechanisms to decrease off-target editing in genomes and enhance the efficiency of targeted insertions. Multiple prime editors developed within a short span of time are a testament to the potential of this technique for targeted insertions. This is mainly because of the possibility of generation of all types of mutations including deletions, insertions, transitions and transversions. Prime editing reverses several bottlenecks of gene editing technologies that limit the biotechnological applicability to produce designer crops...
February 16, 2024: Journal of Experimental Botany
https://read.qxmd.com/read/38268817/-ex-vivo-comparative-immunogenicity-assessment-evcia-to-determine-relative-immunogenicity-in-chronic-plaque-psoriasis-in-participants-receiving-humira-%C3%A2-or-undergoing-repeated-switches-between-humira-%C3%A2-and-avt02
#11
JOURNAL ARTICLE
Kathleen Richter, Halimu N Haliduola, Jana Schockaert, Aurélie Mazy, Nataliya Reznichenko, Eric Guenzi, Fausto Berti
Immunogenicity against biologic medicines is ubiquitous, and it is traditionally measured by the final humoral response. However, the onset of a sustained immunogenic response begins at the cellular level with activation of T cells and maturation of naïve B cells into plasma cells. Ex vivo comparative immunogenicity assessment (EVCIA) of cellular immunogenicity in participants with moderate-to-severe chronic plaque psoriasis in the AVT02-GL-302 study, who received either reference product (RP) alone (non-switching arm) or switched between RP and AVT02 (switching arm) after 1:1 randomization at week 12...
2024: Immunotherapy advances
https://read.qxmd.com/read/38256537/digital-therapeutics-for-improving-effectiveness-of-pharmaceutical-drugs-and-biological-products-preclinical-and-clinical-studies-supporting-development-of-drug-digital-combination-therapies-for-chronic-diseases
#12
REVIEW
Zack Biskupiak, Victor Vinh Ha, Aarushi Rohaj, Grzegorz Bulaj
Limitations of pharmaceutical drugs and biologics for chronic diseases (e.g., medication non-adherence, adverse effects, toxicity, or inadequate efficacy) can be mitigated by mobile medical apps, known as digital therapeutics (DTx). Authorization of adjunct DTx by the US Food and Drug Administration and draft guidelines on "prescription drug use-related software" illustrate opportunities to create drug + digital combination therapies, ultimately leading towards drug-device combination products (DTx has a status of medical devices)...
January 11, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38250743/the-totality-of-evidence-approach-in-the-development-of-avt02-adalimumab-a-biosimilar-to-humira
#13
REVIEW
Joseph E McClellan, Sesselja Ómarsdóttir, Nivedita Roy, Verena Berger, Cecilia Michel, Fausto Berti
The development of a biosimilar is based on comparative structural, physicochemical, functional and clinical assessments. The sum of these analyses encompasses the 'totality of evidence', which demonstrates no clinically meaningful differences between the biosimilar and the reference product (RP). Once biosimilarity has been established, provided there is suitable scientific justification, clinical data may be extrapolated to other indications of the RP. AVT02 has been developed as a biosimilar to high-concentration, low-volume Humira (adalimumab), an anti-tumour necrosis factor-alpha monoclonal antibody approved for various chronic inflammatory indications...
2024: Therapeutic Advances in Chronic Disease
https://read.qxmd.com/read/38222988/cerebral-tuberculosis-after-therapy-with-adalimumab-for-hidradenitis-suppurativa-a-rare-case
#14
Francisca Martins, Alexandra Rodrigues, João Fonseca Oliveira, Rui Malheiro, Luís Cerqueira
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with limited therapeutic options. Adalimumab, an anti-tumor necrosis factor-alpha (TNF-α) monoclonal antibody, was the first biological agent approved for the treatment of moderate to severe HS. Tuberculosis (TB) is a highly prevalent global public health problem, affecting individuals worldwide. Continuous immunosuppression from TNF-α treatment increases the risk of TB development. Isolated neurotuberculosis, in the absence of other symptoms, emerges as a rarely observed infection pattern in such patients...
January 2024: Curēus
https://read.qxmd.com/read/38212257/bimekizumab-bimzelx-for-psoriasis
#15
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
January 22, 2024: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/38194436/efficacy-and-safety-of-switching-from-adalimumab-originator-to-sb5-adalimumab-biosimilar-for-noninfectious-uveitis
#16
JOURNAL ARTICLE
Seok Hyeon Song, Se Joon Woo
PURPOSE: To evaluate the efficacy and safety of switching from adalimumab originator (Humira, AbbVie) to SB5, adalimumab biosimilar (Adalloce, Samsung Bioepis) in patients with noninfectious uveitis (NIU). METHODS: Fifteen patients (29 eyes) with NIU who were switched from adalimumab originator to SB5 and followed up for 6 months or longer were retrospectively included. Data consisted of best-corrected visual acuity (BCVA, logMAR), intraocular pressure (IOP, mmHg), anterior chamber (AC) cell grade, anterior vitreous (AV) cell grade, vitreous haze grade, central macular thickness (CMT, μm), and macular volume (MV, mm3 ) at pre-switching, 2, 4, and 6 months post-switching...
January 9, 2024: Ocular Immunology and Inflammation
https://read.qxmd.com/read/38161925/drug-induced-hidradenitis-suppurativa-a-case-report
#17
Abraham Kisule, Vivek Kak, Chidamber Alamelumangapuram, Ciji Robinson
Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory disorder of the hair follicles that localizes to the intertriginous and anogenital regions of the body. Lesions are characterized by inflammatory nodules, subcutaneous abscesses, fibrosis, and sinus tracts. Crohn's disease (CD) is an idiopathic chronic inflammatory bowel disease that affects any part of the gastrointestinal tract. Multiple treatment options exist for CD, including monoclonal anti-tumor necrosis factor alpha (TNF-α) antibodies like adalimumab (Humira)...
November 2023: Curēus
https://read.qxmd.com/read/38111376/structure-based-development-of-a-canine-tnf-%C3%AE-specific-antibody-using-adalimumab-as-a-template
#18
JOURNAL ARTICLE
Cheng-Chung Lee, Wen-Chih Kuo, Ya-Wen Chang, Shu-Fang Hsu, Chia-Hung Wu, Ya-Wen Chen, Jui-Jen Chang, Andrew H-J Wang
The canine anti-TNF-α monoclonal antibody is a potential therapeutic option for treating canine arthritis. The current treatments for arthritis in dogs have limitations due to side effects, emphasizing the need for safer and more effective therapies. The crystal structure of canine TNF-α (cTNF-α) was successfully determined at a resolution of 1.85 Å, and the protein was shown to assemble as a trimer, with high similarity to the functional quaternary structure of human TNF-α (hTNF-α)...
December 19, 2023: Protein Science
https://read.qxmd.com/read/38023923/editorial-leveraging-genomics-phenomics-and-plant-biotechnology-approaches-for-improving-abiotic-and-biotic-stress-tolerance-in-cereals-and-legumes
#19
EDITORIAL
Paola Leonetti, Moemen S Hanafy, Rupesh Tayade, Muthusamy Ramakrishnan, Humira Sonah, Hans-Joerg Jacobsen
No abstract text is available yet for this article.
2023: Frontiers in Plant Science
https://read.qxmd.com/read/38007078/electrochemical-and-computational-insights-into-the-utilization-of-2-2-dithio-bisbenzothiazole-as-a-sustainable-corrosion-inhibitor-for-mild-steel-in-low-ph-medium
#20
JOURNAL ARTICLE
Humira Assad, Sourav Kr Saha, Namhyun Kang, Suresh Kumar, Praveen Kumar Sharma, Hariom Dahiya, Abhinay Thakur, Shveta Sharma, Richika Ganjoo, Ashish Kumar
Industries today place a high premium on environmentally friendly supplies that may effectively inhibit metal dissolution at a reasonable cost. Hence, in this paper, we assessed the corrosion inhibition effectiveness of the Thiazole derivative namely, 2, 2-Dithio Bisbenzothiazole (DBBT) against mild steel (MS) corrosion in 1 M HCl. Several experimental approaches, including gravimetric analysis, potentiodynamic polarization (PDP), electrochemical impedance spectroscopy (EIS), and surface exploration using scanning electron/atomic force microscopy (SEM/AFM) and contact angle (CA), were utilized to conduct the measurements...
November 23, 2023: Environmental Research
keyword
keyword
9699
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.